AMWL just delivered its Q1 2026 results and the Street reacted — not with alarm, but with a quiet re-rating that pushes the digital health company's stock toward the centre of its analyst target range for the first time in months.
Options told the story first. After trading with heavy defensive skew for most of April — the put/call ratio ran above 1.5 for three consecutive weeks — sentiment flipped sharply on Tuesday evening. The PCR collapsed to 0.41, nearly 2.75 standard deviations below its 20-day average of 1.65. That's a near-180-degree turn in options positioning: where traders were hedging hard into the print, call activity now overwhelmingly dominates. The reading is close to the lowest put/call ratio AMWL has seen in the past year, against a 52-week low of 0.07. The shift is stark, and it happened in a single session.
The earnings print itself earned that reaction. Q1 EPS came in at $(0.66), comfortably ahead of the $(1.15) consensus estimate. Revenue of $54.9 million beat the $51.5 million estimate, and the company reaffirmed full-year 2026 sales guidance of $195–$205 million — bracketing the Street's $199 million estimate. Management highlighted higher-than-expected renewals and retention rates despite the headline revenue decline year-on-year, a sign the subscription base is holding more firmly than feared. The sequential improvement in net loss — down to $10.9 million from $24.9 million in Q4 2025 — adds to the picture of a leaner cost structure.
Two analysts responded on May 6th. TD Cowen maintained its Hold but raised its target from $5.00 to $8.00 — a 60% move that brings the firm's view in line with Morgan Stanley, which also maintained Equal-Weight and lifted its target from $6.00 to $6.50. Both actions point in the same direction: the bar was set low, the print cleared it, and the near-term risk is less severe than previously priced. The consensus remains a neutral Hold across five covering analysts, with a mean price target of $7.50 against a current price of $6.36 — implying roughly 18% upside on paper. No analyst has moved to a Buy following the print, which keeps the setup in "good enough, not great" territory. The EPS surprise factor score sits at the 58th percentile, decent rather than exceptional.
Short positioning is a minor thread here, not a central one. SI is running at just 2.1% of the free float — not a level that generates material squeeze dynamics. It has drifted about 18% higher over the past month, from roughly 264,000 shares short in late March to around 311,000 now, but the moves are gradual and the borrow market remains relaxed. Cost to borrow is 0.53% — not far from where it's been for the past six weeks — and availability has been well above the floor. There's no meaningful pressure building in the lending market.
The ownership picture is worth a brief note. Cable Car Capital built a fresh 810,000-share position as of January 16, making it the second-largest institutional holder at 4.85% of shares. Senvest Management added 375,000 shares in February, taking its stake to 4.4%. Both are active managers, and both entered during the period when the stock was trading in the $5–$6 range. Against that, the co-founders Roy and Ido Schoenberg each trimmed modestly through year-end 2025, and the CTO and President have continued small, routine share sales — values well below $30,000 each — through the first quarter. The pattern looks more like tax-driven plan sales than a signal of deteriorating conviction at the top.
The next scheduled catalyst is a Q2 report currently flagged for June 16. Between now and then, the key question is whether the renewal strength flagged in Q1 translates into subscription revenue stabilisation — the bull case rests almost entirely on Digital Health Application (DHA) subscription growth to offset declining visit volumes, and Q2 guidance of $48–$52 million in revenue keeps the full-year target achievable rather than ambitious.
See the live data behind this article on ORTEX.
Open AMWL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
